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Cardiovascular disease (CVD) is a major cause of mortality accounting for 27% of 
deaths in the United Kingdom (UK) in 2014 and is a great cost to the UK economy, 
estimated to be £15.2 billion in 2015.[1] Lipid modification is important as there is a 
positive correlation between the incidence of CVD and cholesterol levels.[2] There is 
substantial evidence of benefit in prescribing statins to all patients for secondary 
prevention of CVD and for primary prevention in many of those patients with higher 
CVD risk.[3] A Cochrane review in 2013 included 18 randomised controlled trials of 
statin prescribing for primary prevention and reported a reduction in all-cause 
mortality (OR 0.86, 95% CI 0.79 to 0.94), with the number needed to treat to 
prevent one death over five years being 96 and an acceptable cost-effectiveness.[3] 
The Cholesterol Treatment Trialists' Collaboration (CTTC) trial performed a meta-
analysis of individual patient data from 27 RCTs and reported in 2012 that statin 
therapy reduces the risk of major vascular events even in patients with 5 year CVD 
risks of <5%.[2] 
 
The National Institute for Health and Care Excellence (NICE) guidance recommends 
the use of the QRISK2 tool to assess CVD risk, and treatment with statins at a >10% 
ten year risk of developing CVD. This guidance was revised from a >20% risk in 
2014 and a >30% risk in 2010.[4] If the current NICE guidance was fully 
implemented in the UK, it has been estimated that 21% more men aged between 40 
and 75 years and 25% more women aged between 55 and 75 years would be 
receiving statins after ten years of monitoring.[5] Virtually all individuals over 75 
years will have a >10% risk of developing CVD in ten years, as the average 10 year 
risk of CVD without risk factors for males is 25.7%, and for females 19.6%.[6] 
Despite this evidence base and these guidelines, primary care prescribing rates of 
statins for primary prevention are lower than predicted.[7] Why might this be? 
 
The causes of variations in the rate of statin prescribing in primary care are 
multifactorial and influenced by both clinician and patient factors. Qualitative 
research has identified several factors which include perceived reduced cost-
effectiveness, excess workload, patient reluctance to take medication when they are 
asymptomatic, potential side effects and medicalisation of healthy individuals.[7] 
Other research has identified substantive overuse of statins in patients with low 
CVD risk and conversely underuse in those with high CVD risk and some of these 
variations are thought to be influenced by single risk factors such as age > 65years, 
diabetes and hypercholesterolaemia.[8] An understanding of how GPs arrive at a 
decision to make primary prevention interventions is critical. GPs have reported 
concern about the clarity of the evidence base and a reluctance to prescribe at lower 
primary prevention thresholds.[7,8] There is sparse literature regarding the views 
of GPs and further qualitative work within our department aims to explore this 
complex issue.  
 
Barriers to prescribing statins for those at lower CVD risk include the transferability 
of the evidence from research into practice and the potential for side effects, 
especially diabetes. Regarding the transferability of the evidence, the majority 
(14/18) of the studies included in the Cochrane review included high risk patients 
such as those with diabetes, hypercholesterolaemia and hypertension.[3] The CTTC 
study used a risk scoring system that is not reproducible in primary care patients, 
unlike QRISK2 or Framingham.[2] The majority of randomised controlled trials 
using statins are of less than 5 years duration, whereas patients are started on 
statins with the intention of it being life-long.[2] Regarding the risk of diabetes, the 
Cochrane review reported an increased relative risk of 1.18 (95% CI 1.01 to 1.39), 
though only two out of the 18 studies in this meta-analysis reported the risk of new 
cases of diabetes.[3] A meta-analyses of 17 randomised controlled trials has 
reported an increased risk of diabetes  (odds ratio 1.09 95% CI 1.02-1.17), with no 
differing treatment effects between statins.[10] 
 
How do we solve this mismatch between the guidelines and evidence base (which 
support the use of statins in lower risk primary prevention individuals) and 
prescribing behaviour of GPs, who appear reluctant to prescribe statins for primary 
prevention to low risk individuals? First, there should be longer-term follow up of 
participants in existing trials for both adverse and beneficial outcomes, and trial 
datasets made available. Second, large randomised controlled trials are needed 
examining the effectiveness of statins in primary prevention which should be 
powered to look specifically at side effects. Thirdly, high quality observational data 
are needed to investigate if the treatment effects of statins reported within the trials 
are reproducible in a typical low risk primary care population. These suggestions 
should be complemented by research exploring patient-centred care and shared 
decision making for asymptomatic patients who are recommended statin therapy. 
There is some evidence that patients will heed the advice of their doctor [11] and it 
is therefore essential that doctors have an adequate and transferable evidence base 
on which to counsel their individual patients. For the moment GPs should continue 
to have a conversation with patients around the current evidence for statins in 
primary prevention. After understanding a patient’s needs and preferences, the 
good doctor sets out the evidence in an understandable way and allows the patient 
to weigh up whether the benefit might outweigh the risk. We acknowledge that 
trying to provide this detailed and complex information can be challenging for a GP 
to deliver and certainly challenging for a patient to understand.[12]  For a patient 
with a 10 year risk of >10% for CVD who would respond to quantitative data the 
above evidence might be communicated in the following way: 
 
“If 96 patients with similar risks to you were to take a statin tablet every day for five 
years then one life might have been saved.[3] However those patients taking statins 
are more likely to develop diabetes; if 225 patients took a statin for 4 years then 
perhaps one might develop diabetes as a side effect;[13]  it is possible that this risk 
of developing diabetes gets higher if you take the statin tablet for a very long 
time.[14]’’ Given this evidence, it might not be surprising that many patients may 
choose not to take statins for primary prevention where benefit appears marginal 
and there is a risk of diabetes. 
 
A simple one-size fits all approach will not meet the needs of patients and doctors; a 
process that allows consideration of individual patient characteristics and choices is 
needed. NICE should provide plain language evidence based statement, such as the 
one above, co-produced with patients and the public to facilitate shared decision 
making. It is unlikely that the NICE guidelines for prescribing statins for primary 
prevention will be closely adhered to by GPs or accepted by patients until these 
uncertainties are resolved. 
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